Olema Pharmaceuticals (OLMA) said Friday that the OP-3136 molecule, which selectively inhibits lysine acetyltransferase 6 in prostate, ovarian, and non-small cell lung cancer models, has shown anti-tumor activity in preclinical studies.
The OP-3136 molecule showed potent anti-proliferative activity in multiple ovarian, NSCLC and prostate cell lines in vitro during the studies. It showed activity that was independent of KAT6 amplification or over expression, and demonstrated anti-tumor activity in vivo xenograft models of ovarian, NSCLC and prostate cancers.
The results indicate that this treatment could be effective in treating these types of tumors in addition to breast cancer, according to the announcement.
The biopharmaceutical company said it will present the preclinical data at the American Association for Cancer Research annual meeting in Chicago, Illinois, happening between April 25 and April 30.
The FDA cleared the investigational new drug application for OP-3136 in December 2024. Currently, patients are enrolling in the phase 1 clinical trial of OP-3136, the company said.
Price: 4.94, Change: -0.16, Percent Change: -3.14
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.